Testing cemiplimab before surgery for Merkel cell carcinoma
Treatments studied
Part of Cancer, Infections, Skin clinical trials.
This trial tests whether giving the immunotherapy drug cemiplimab before surgery can improve outcomes for people with stage I or II Merkel cell carcinoma. If you qualify, you would receive cemiplimab before your sentinel lymph node biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Merkel cell carcinoma at stage II, or stage I with a tumor at least 1 cm (about 0.4 inches) across.
- You are 18 years or older.
- Your primary tumor has already been removed, but you still need a sentinel lymph node biopsy.
- Your overall health is good (ECOG performance status 0-2).
- You have adequate organ function (kidneys, liver, blood counts).
- If you can become pregnant, you must agree to use highly effective birth control during treatment and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
This trial tests a combination of two immunotherapy drugs, nivolumab and relatlimab, before surgery for Merkel cell carcinoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests pembrolizumab (an immune therapy) given before surgery to shrink Merkel cell carcinoma and improve outcomes. Participants also have extra tumor biopsies to study biomarkers, which may help explain who benefits most.
This trial tests giving Cemiplimab, an immunotherapy drug that helps your immune system fight cancer, before surgery to remove early stage non-small cell lung cancer. It aims to see if this approach can improve outcomes for people with small tumors that are more aggressive based on PET scan activity or cell appearance.
This trial tests if the immunotherapy drug cemiplimab, given before and after surgery, can help treat early-stage non-small cell lung cancer that has high levels of a protein called PD-L1. If you have stage II or IIIA lung cancer that can be surgically removed and your tumor has PD-L1 expression of 50% or more, you may be eligible.
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
Hear when a new Neoadjuvant Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.